NBRVF

0.00010.00%
HM

H. Michael Hogan

Chief Executive Officer

Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from February 2023. He had been Vice President of Calico Commerce, Inc. since August 2001 till 2003. He is a representative of Armanino LLP. He has served as a Partner at Armanino LLP (“Armanino”), a top 20 U.S. full-service firm providing tax, assurance and consulting services to clients in the nation’s emerging markets, since January 2021, and leads the firm’s Corporate Finance and Restructuring practices. From October 2016 to January 2021, Mr. Hogan served as a Managing Director in the firm’s Corporate Finance and Restructuring practice. Prior to his time at Armanino, Mr. Hogan served as a Managing Director at Sherwood Advisory Services, with a focus on advisory and managerial services for distressed companies. Mr. Hogan also serves as the Vice President of Finance and Administration, Chief Financial Officer and Secretary of Accelerated Networks. He served as Senior Vice President of Finance, Chief Financial Officer and Secretary of 3D Systems Corporation from September 1999 to February 2001. Mr. Hogan has been a Principal of Regent Pacific, the professional services firm that is currently providing Calico Commerce Inc. with management services, since November 1996. Mr. Hogan holds a B.A. in Political Science and Economics from Colgate University and is a Certified Insolvency Reorganization Accountant and a Certified Turnaround Professional.

Positions